Document 0242
 DOCN  M9440242
 TI    Heterosexual transmission of human immunodeficiency virus type 1
       variants associated with zidovudine resistance.
 DT    9404
 AU    Conlon CP; Klenerman P; Edwards A; Larder BA; Phillips RE; Infectious
       Diseases Unit, Nuffield Department of Clinical; Medicine, John Radcliffe
       Hospital, Oxford, United Kingdom.
 SO    J Infect Dis. 1994 Feb;169(2):411-5. Unique Identifier : AIDSLINE
       MED/94149330
 AB    During zidovudine therapy, human immunodeficiency virus type 1 (HIV-1)
       acquires a distinctive set of mutations that diminish the sensitivity of
       the virus to this drug in vitro. An AIDS patient is described who, while
       being treated with zidovudine, transmitted HIV-1 bearing a drug
       resistance mutation to a young woman who had never received zidovudine
       treatment. DNA sequencing of HIV-1 proviruses confirmed that these 2
       persons shared HIV genetic variants, including a mutation at codon 70 in
       the reverse transcriptase gene associated with reduced in vitro
       sensitivity to zidovudine. This mutation persisted in the woman > 1 year
       in the absence of antiretroviral therapy. HIV-1 with genetic markers of
       zidovudine resistance can be transmitted heterosexually, but it is
       uncertain whether dissemination of drug-resistant virus will
       substantially reduce the usefulness of this drug.
 DE    Adult  Base Sequence  Case Report  Drug Resistance, Microbial  DNA
       Primers/CHEMISTRY  Female  Human  HIV Infections/*TRANSMISSION
       HIV-1/*DRUG EFFECTS  Male  Molecular Sequence Data  Point Mutation
       Polymerase Chain Reaction  Reverse Transcriptase/GENETICS  Sex Behavior
       Support, Non-U.S. Gov't  Time Factors  Variation (Genetics)
       Zidovudine/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).